While the dollar volume is not large relative to market cap, the coordinated selling by the CEO, CMO, and other executives raises caution, especially ahead of potential catalysts. Monitor upcoming earnings or clinical trial updates for confirmation of business momentum. Consider this a warning sign if no positive news follows.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $28.78entry
- T+1 · 7mo ago −0.69%α −1.91% · $28.58
- T+5 · 7mo ago −5.18%α −6.16% · $27.29
- T+20 · 6mo ago +14.45%α +8.64% · $32.94
- T+60 · 4mo ago +21.86%α +14.81% · $35.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four corporate insiders at Pharvaris N.V. (PHVS) sold shares in a concentrated 7-day window, including CEO Berndt Modig who sold $66K worth of stock. The total open-market sales amount to approximately $219,000, with additional non-cash derivative exercises that do not represent economic dispositions. This represents a modest but notable insider selling cluster involving key C-suite executives.
Key Financial Metrics
Key Facts
- CEO Berndt Modig sold 2,300 shares for $66,000 on April 16, 2026, at $28.60 per share.
- Chief Medical Officer Lu Peng sold 7,101 shares across two transactions totaling $213,405 (including $210,402 on April 22 and $3,003 on April 23).
- Chief Early Development Anne Lesage sold 600 shares for $18,003 across two dates (April 22 and 23).
- Director Schikan sold 7,100 shares for $213,382 (April 22 and 23).
- Total open-market sales by insiders: ~$429,000 over 7 days.
- Multiple non-cash derivative exercises occurred (transaction codes A, M, F), totaling $0 in economic value.
- Cluster involves three C-suite executives and one director, increasing signal relevance.
Financial Impact
$429,000 in total open-market insider sales over 7 days, representing ~0.024% of $1.8B market cap, modest in scale but notable due to participation by top executives.
Risk Factors
- Insider selling may signal reduced confidence in near-term valuation or upcoming headwinds.
- Non-cash derivative exercises could indicate routine option expirations rather than strategic economic decisions, but open-market sales are more meaningful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1777054200768 |
Track record
51 reports on PHVS
14 of 17 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers